The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.
David Roodman is leading research to investigate a molecule that could repair bone, decrease tumors and improve outcomes for multiple myeloma patients on specific targeted therapies.
Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory (persistent) multiple myeloma. The study was selected as the prestigious plenary presentation at the 61st American Society of Hematology (ASH) Annual Meeting, the world’s leading conference for hematologic cancers and blood disorders, held in Orlando in December.